Edward P. Acosta

University of Alabama, Birmingham, Birmingham, AL, United States 
Pharmacology, Pharmaceutical Chemistry
"Edward P. Acosta"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Cressey TR, Hazra R, Wiznia A, et al. (2016) Pharmacokinetics of Unboosted Atazanavir in Treatment-Experienced HIV-infected Children, Adolescents and Young Adults. The Pediatric Infectious Disease Journal
Cressey TR, Yogev R, Wiznia A, et al. (2016) Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults. Journal of the Pediatric Infectious Diseases Society
Rizk ML, Du L, Bennetto-Hood C, et al. (2015) Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age. Journal of Clinical Pharmacology. 55: 748-56
Larson KB, Wang K, Delille C, et al. (2014) Pharmacokinetic enhancers in HIV therapeutics. Clinical Pharmacokinetics. 53: 865-72
Clarke DF, Acosta EP, Rizk ML, et al. (2014) Raltegravir pharmacokinetics in neonates following maternal dosing. Journal of Acquired Immune Deficiency Syndromes (1999). 67: 310-5
Delille CA, Pruett ST, Marconi VC, et al. (2014) Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. Journal of Clinical Pharmacology. 54: 1063-71
Li JZ, Chapman B, Charlebois P, et al. (2014) Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. Plos One. 9: e90485
Wang K, D'Argenio DZ, Acosta EP, et al. (2014) Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients. Clinical Pharmacokinetics. 53: 361-71
Acosta EP, Grigsby PL, Larson KB, et al. (2014) Transplacental transfer of Azithromycin and its use for eradicating intra-amniotic ureaplasma infection in a primate model. The Journal of Infectious Diseases. 209: 898-904
Nachman S, Zheng N, Acosta EP, et al. (2014) Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 58: 413-22
See more...